Evaluations

February 7, 2020
  1. Mould DR*, Dubinsky MC. “Dashboard Systems: Pharmacokinetic / Pharmacodynamic Mediated Dose Optimization.” J Clin Pharmacol. 2015;55 Suppl 3:S51-9
  2. Melmed GY*, Irving PM, Jones J, Kaplan GG, Kozuch PL, Velayos FS, Baidoo L, Sparrow MP, Bressler B, Cheifetz AS, Devlin SM, Raffals LE, Vande Casteelle N, Mould DR, Colombel J-F, Dubinsky M, Sandborn WJ, Siegel CA. “Appropriateness of Testing and Interpretation of anti-TNF Drug and Antibody Concentrations: When should they be ordered, and what to do with the results?” Clin Gastroenterol Hepatol. 2016 ;14(9):1302-9
  3. Dubinsky MC*, Phan BL, Singh N, Rabizadeh S, Mould DR. “Pharmacokinetic dashboard recommended dosing is different than standard of care dosing in infliximab treated pediatric IBD patients.” AAPS J. 2017 ;19(1):215-222
  4. Mould DR*, Upton RN, Wojciechowsk J, Phan BL, Tse S, Dubinsky MC. “Dashboards For Therapeutic Monoclonal Antibodies: Learning and Confirming.” AAPS J 2018;20(4):76 [epub]
  5. Strik AS, Wang Y-M C, Ruff L, Yashar W, Messmer B, Mould DR. “Individualized Dosing of Therapeutic Monoclonal Antibodies – A Changing Treatment Paradigm” AAPS J 2018; 20(6):99 [epub]
  6. Turner D*, Griffiths A, Wilson DC, Mould DR, Baldassano R, Russell RK, Dubinsky MC, Heyman MB, de Ridder L, Hyams JS, Martín-de-Carpi J, Conklin LS, Faubion WA, Koletzko S, Bousvaros A, Ruemmele FM. Designing clinical trials in pediatric inflammatory bowel diseases – a PIBDnet commentary. GUT 2019; epub.
  7. Mould DR*, D’Haens G, Upton RN. “Clinical Decision Support Tools: The Evolution of a Revolution.” Clin Pharmacol Ther. 2016;99(4):405-18
  8. Brandse JF*, Mould DR, Ashruf YK, Smeekes OS, Kuin S, van den Brink GR, D’Haens GR. “A Real-life Population Pharmacokinetic Study Reveals Factors Associated with Clearance and Immunogenicity of Infliximab in Inflammatory Bowel Disease.” Inflam Bowel Dis. 2017 ;23(4):650-660
  9. Vande Casteele N*, Mould DR, Coarse J, Hasan I, Gils A, Feagan B, Sandborn WJ. “Accounting for Pharmacokinetic Variability of Certolizumab Pegol in Patients with Crohn’s Disease.” Clin Pharmacokinet. 2017; 56(12):1513-1523
  10. Vande Casteele N, Mould DR, Tops S, Vandenbroeck K, Ballet V, Ferrante M, Van Assche G, Gils A, Vermeire S, Baert F. “Initial Adequate Trough Concentrations during Induction Therapy Correlate with Sustained TNF Suppression and Predict Remission with Adalimumab in Anti-TNF Naïve Crohn’s Disease Patients” ECCO 2015 Barcelona Spain

Abstracts

  1. J.F. Brandse, D.R. Mould, Y.K. Ashruf, O. Smeekes, S. Kuin, A. Strik, G.R. van den Brink, G.R. D’Haens. “Therapeutic Drug Monitoring in Inflammatory Bowel Disease”. DDW 2016 San Diego CA
  2. Strik A, Berends S, Mould DR, Mathôt R, Ponsioen C, van den Brande J, Jansen J, Hoekman D, Brandse J, Löwenberg M, D’Haens G. Dashboard driven versus conventional dosing of infliximab in inflammatory bowel disease patients: the PRECISION trial 2019 ECCO Copenhagen Denmark
  3. Strik A, Berends S, Mould DR, Mathôt R, Ponsioen C, van den Brande J, Jansen J, Hoekman D, Brandse J, Löwenberg M, D’Haens G. Dashboard driven versus conventional dosing of infliximab in inflammatory bowel disease patients: the PRECISION trial 2019 DDW San Diego CA USA
  4. Melmed GY, Irving PM, Jones J, Kaplan GG, Kozuch PL, Velayos FS, Baidoo L, Sparrow MP, Bressler B, Cheifetz AS, Devlin SM, Harrell LE, Vande Casteelle N, Mould DR, Dubinsky M, Colombel JF, Sandborn WJ, Siegel CA. “The Appropriateness of Testing and Interpretation of Anti-TNF Drug and Antibody Concentrations: When Should They be Ordered and What to Do With the Results?” UEGW October 2014 Vienna Austria
  5. Melmed GY, Irving PM, Jones J, Kaplan GG, Kozuch PL, Velayos FS, Baidoo L, Sparrow MP, Bressler B, Cheifetz AS, Devlin SM, Harrell LE, Vande Casteelle N, Mould DR, Dubinsky M, Colombel JF, Sandborn WJ, Siegel CA. “Interpretation of anti-TNF Drug Concentration and Antibody Levels: What to do with the results in different clinical scenarios?” ACG October 2014 Philadelphia PA
  6. Vande Casteele N, Mould DR, Tops S, Vandenbroeck K, Ballet V, Ferrante M, Van Assche G, Gils A, Vermeire S, Baert F. “Initial Adequate Trough Concentrations during Induction Therapy Correlate with Sustained TNF Suppression and Predict Remission with Adalimumab in Anti-TNF Naïve Crohn’s Disease Patients” ECCO 2015 Barcelona Spain
  7. Dubinsky M; Singh N; Mould DR. “Using a pharmacokinetic dashboard to forecast infliximab levels and predict individualized dosing regimens in IBD patients” ECCO 2015 Barcelona Spain
  8. Vande Casteele N, Mould DR, Tops S, Vandenbroeck K, Ballet V, Ferrante M, Van Assche G, Gils A, Vermeire S, Baert F. “Initial Adequate Trough Concentrations during Induction Therapy Correlate with Sustained TNF Suppression and Predict Remission with Adalimumab in Anti-TNF Naïve Crohn’s Disease Patients” DDW 2015 Washington DC
  9. Dubinsky M; Singh N; Mould DR. “Using a pharmacokinetic dashboard to forecast infliximab levels and predict individualized dosing regimens in IBD patients” DDW 2015 Washington DC
  10. Stewart, MJ; Dubinsky M; Morganstern B; Vasiliauskas E; Targan ; Ippoliti A; Shih DQ; Mould DR; McGovern D; Melmed, GY. The Steady-State Pharmacokinetics of Adalimumab: Do We Need to Drink From the “Trough”? DDW Annual Meeting 2016
  11. MJ Stewart, M Dubinsky, B Morganstern, E Vasiliauskas, S Targan, A Ippoliti, DQ Shih, D Mould, D McGovern, GY.Melmed. “The Steady-State Pharmacokinetics of Adalimumab: Do We Need to Drink From the “Trough?”. DDW 2016 San Diego CA
Back To Top